David W. Meyer
Impact in
- Oncology top 5%
- HER2/EGFR in Cancer Research
- CAR-T cell therapy research
- Peptidase Inhibition and Analysis
-
- Monoclonal and Polyclonal Antibodies Research
Papers in
- Oncology 13
- HER2/EGFR in Cancer Research 11
- Cancer Treatment and Pharmacology 2
-
- Monoclonal and Polyclonal Antibodies Research 11
- Co-authors
- Peter D. Senter (8 shared papers)Martha E. Anderson (8 shared papers)Jamie B. Miyamoto (5 shared papers)Patrick Burke (5 shared papers)Jonathan M. Scholey (2 shared papers)Douglas G. Cole (2 shared papers)Scott C. Jeffrey (7 shared papers)Dana J. Rashid (1 shared paper)
- Journals
- Cancer Research (5 papers)Molecular Cancer Therapeutics (2 papers)Bioconjugate Chemistry (2 papers)PROTEOMICS - CLINICAL APPLICATIONS (1 paper)Bioorganic & Medicinal Chemistry Letters (1 paper)
- Partner nations
- United StatesGermany
In The Last Decade
David W. Meyer
17 papers receiving 792 citations
Peers
Comparison fields: 5 of 62
- Oncology 462
- Radiology, Nuclear Medicine and Imaging 355
- Hematology 104
- Cell Biology 116
- Molecular Biology 364
Countries citing papers authored by David W. Meyer
This map shows the geographic impact of David W. Meyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David W. Meyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David W. Meyer more than expected).
Fields of papers citing papers by David W. Meyer
This network shows the impact of papers produced by David W. Meyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David W. Meyer. The network helps show where David W. Meyer may publish in the future.
Co-authors
The 25 scholars most cited alongside David W. Meyer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2013 | 309 | |
| 2 | 2008 | 148 | |
| 3 | 1996 | 128 | |
| 4 | 2009 | 86 | |
| 5 | 2018 | 49 | |
| 6 | 2018 | 33 | |
| 7 | 2020 | 27 | |
| 8 | 2009 | 21 | |
| 9 | 2014 | 13 | |
| 10 | 2015 | 6 | |
| 11 | 1998 | 5 | |
| 12 | 2020 | 3 | |
| 13 | 2012 | 2 | |
| 14 | 2011 | 2 | |
| 15 | 2012 | 2 | |
| 16 | 2020 | 2 | |
| 17 | 2021 | 2 | |
| 18 | 2014 | 1 |
About David W. Meyer
David W. Meyer is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging, Molecular Biology, Organic Chemistry and Cell Biology, having authored 18 papers that have together received 839 indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (11 papers), HER2/EGFR in Cancer Research (11 papers), Click Chemistry and Applications (2 papers), Ubiquitin and proteasome pathways (2 papers), Microtubule and mitosis dynamics (2 papers), Cancer therapeutics and mechanisms (2 papers), Protist diversity and phylogeny (2 papers) and Cancer Treatment and Pharmacology (2 papers). The work is most often cited by research in Oncology (462 citations), Radiology, Nuclear Medicine and Imaging (355 citations), Hematology (104 citations), Cell Biology (116 citations) and Molecular Biology (364 citations). David W. Meyer has collaborated with scholars based in United States and Germany. Frequent co-authors include Peter D. Senter, Martha E. Anderson, Jamie B. Miyamoto, Patrick Burke, Jonathan M. Scholey, Douglas G. Cole, Scott C. Jeffrey, Dana J. Rashid, Karen P. Wedaman and Robert P. Lyon. Their work appears in journals such as Cancer Research, Molecular Cancer Therapeutics, Bioconjugate Chemistry, PROTEOMICS - CLINICAL APPLICATIONS and Bioorganic & Medicinal Chemistry Letters.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.